Development of Diagnostics and Treatment of Urological Cancers
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 100
- 试验地点
- 2
- 主要终点
- Successful clinical translation
研究概览
简要总结
The purpose of the study is to evaluate whether state-of-the-art technologies such and next generation sequencing and drug sensitivity and resistance testing of patient derived tumour tissue can facilitate research translation and improve outcome of urologic cancers.
详细描述
Access to high-quality clinical patient material (e.g. tissue of primary tumor and metastasis, plasma and urine) linked to comprehensive registry and clinical data and molecular characterization of the patient material using state-of-the-art technologies (e.g. NGS, transcriptomics, imaging, DSRT) will facilitate a more rapid translation of basic research innovations into clinical care (diagnostics, imaging, therapeutics) and result in improved outcome of patients suffering from urologic cancers ("personalized medicine").
The principal aim of the project is to establish a framework and infrastructure for the systematic collection and interpretation of biological patient samples. Similarly, the investigators aim to establish the format how the related clinical and research data can be made readily accessible for both clinicians and researchers without compromising patient privacy. The key objectives of the project are to facilitate research translation and to improve outcome of urologic cancers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient is able to provide written informed consent and is at least 18 years of age
- •The patient must have a verified diagnosis of an urologic cancer by a board-certified clinician
排除标准
- •The patient is not willing to provide a written informed consent
- •The patient has a severe psychiatric illness, imprisonment or mental impairment inflicting on ability to give informed consent
结局指标
主要结局
Successful clinical translation
时间窗: Up to 24 months
The magnitude of successful clinical translation is measured by the number of times project-derived personalized medicine has impacted patients care by application of novel and existing biomarkers and therapies (e.g. sequencing, DSRT) by 2020
次要结局
- Successful pre-clinical translation(Up to 24 months)
- Translation of preclinical data into clinically useful data.(Up to 24 months)
- Number of representative cell models developed from clinical samples.(Up to 24 months)
研究者
Antti Rannikko
Senior consultant, urology
Helsinki University Central Hospital